This article will provide an in-depth analysis of drugs being developed to combat cancer. Big Pharma is keenly interested in the global cancer therapeutics market, which is expected to exceed $400 bil...

High beta market sectors, including small caps and biotech, sold off significantly last week as the 10-Year Treasury yield surpassed 4.75%. The JP Morgan Healthcare event in San Francisco that opens t...

Making its debut on 01/31/2006, smart beta exchange traded fund SPDR S&P Biotech ETF (XBI) provides investors broad exposure to the Health Care ETFs category of the market.

Designed to provide broad exposure to the Healthcare - Biotech segment of the equity market, the SPDR S&P Biotech ETF (XBI) is a passively managed exchange traded fund launched on 01/31/2006.

Investing in biotech offers high upside but comes with significant risks, especially with volatile stock movements and binary outcomes from clinical trials, says Jonathan Faison. Focus on multi-year c...

The biotech sector recently experienced a sharp reversal following a failed breakout attempt post-election. While most areas of the market surged to new heights after Donald Trump's election win on No...

Biotech had its worst weekly performance since 2020 last week, driven by the post-election rally fizzling and fears surrounding RFK Jr.'s potential impact on the FDA. Concerns about Mr. Kennedy leadin...

Investors can take advantage of beaten-down prices because the second Trump administration is likely to boost stocks.

SPDR® S&P Biotech ETF is a well-diversified, low-cost ETF that can be an excellent tool to capitalize on the potential of the biotech stock sector. XBI's performance should be compared with the Russel...

The small cap biotech sector is trading close to the same levels that it was five years ago. Straight equity holdings have threaded water in this space over the past half decade. However, given the lu...